Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: A systematic review and cost analysis

Kelly Comerford Wormer, Ayesha A. Jangda, Farah A. El Sayed, Katherine I. Stewart, Sunni L. Mumford, James H. Segars

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations


Background: The majority of serious thromboembolic events occurring in assisted reproductive technologies (ART) are in women with ovarian hyperstimulation syndrome (OHSS). Objectives: The purpose of this study was to present a thorough review and cost analysis regarding the use of venous thromboembolism (VTE) prophylaxis in OHSS to inform clinical management. Data sources: Databases used were Pubmed and Embase, in addition to checking reference lists of retrieved articles (inception to November 2017). Methods: The systematic search strategy identified 365 titles and abstracts. Articles included in the qualitative synthesis had identified venous thrombosis incidence rates or ratios. A separate search for the cost model was conducted recognizing all associated complications of VTE. The decision tree was modeled to best fit the patient population and a sensitivity analysis was performed over a range of variables. Results: The cost of VTE event per OHSS patient not on prophylaxis was €5940 (range €3405 to €38,727), versus €4134 (€2705 to €23,192) per event per patient on prophylaxis, amounting to a saving of (€19 to €23,192) per VTE per patient. Sensitivity analysis found VTE prophyaxis to be cost effective if the incidence of VTE in the OHSS population was greater than 2.79%. Prophylactic therapy was cost effective through 16 weeks of treatment. Limitations: OHSS is infrequent and hence, the incidence of VTE in patients with OHSS is low; therefore, the data used to inform the incidence of VTE in OHSS in the model carry some uncertainty. Further, low molecular weight heparin (LMWH) has side effects therefore individualization of care must be considered. Conclusions: With the increasing incidence of infertility and requirement for ART, thromboembolism in OHSS poses a major health threat for patients. VTE prophylaxis using enoxaparin was cost effective in patients with severe OHSS over a wide range of costs and incidences. Prophylaxis was also cost effective through the completion of the first trimester of pregnancy.

Original languageEnglish (US)
Pages (from-to)117-124
Number of pages8
JournalEuropean Journal of Obstetrics and Gynecology and Reproductive Biology
StatePublished - May 2018


  • Cost analysis
  • Ovarian hyperstimulation syndrome
  • Prophylaxis
  • Venous thromboembolism

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology


Dive into the research topics of 'Is thromboprophylaxis cost effective in ovarian hyperstimulation syndrome: A systematic review and cost analysis'. Together they form a unique fingerprint.

Cite this